Department of Medicine, Tulane University, New Orleans, Louisiana 70115, USA.
Urology. 2010 Mar;75(3):623-9. doi: 10.1016/j.urology.2009.04.059. Epub 2009 Jul 8.
To define current standards of care for patients with prostate-specific antigen (PSA) failure after initial definitive local treatment of prostate cancer using Comprehensive, Observational, Multicenter, Prostate Adenocarcinoma Registry (COMPARE). This article describes the design of the COMPARE Registry, together with patient characteristics and prostate cancer management at enrolment.
The COMPARE Registry is a prospective, multicenter, observational study that collected data on patient characteristics, management practices, and outcomes of men presenting to their physician for the management of an increasing PSA level after definitive (surgical or radiotherapeutic) treatment of localized prostate cancer. Data collected by the physician and reported by the patient at the baseline (enrolment) visit are described.
Between February 2004 and March 2007, 1120 men were enrolled at 150 sites throughout the United States. The men had a median age of 73 years (range, 46-95 years), were predominantly white (77%), and had a median PSA level of 7.9 ng/mL (range, 0-710.8 ng/mL) at diagnosis. Observation (74%) was the most common initial management choice at registry enrolment, and androgen-deprivation therapy (22%) was the most common initial treatment choice.
Data from the COMPARE Registry should provide a valuable source of prospectively collected information on the contemporary management of prostate cancer and patient outcomes after PSA failure.
使用综合、观察性、多中心前列腺腺癌登记处（COMPARE），为初始局部治疗前列腺癌后 PSA 失败的患者定义当前的治疗标准。本文描述了 COMPARE 登记处的设计，以及入组时患者的特征和前列腺癌的管理。
COMPARE 登记处是一项前瞻性、多中心、观察性研究，收集了患者特征、管理实践以及接受明确（手术或放射治疗）治疗后出现 PSA 水平升高的男性患者的管理结局数据。描述了由医生收集并由患者在基线（入组）就诊时报告的数据。
2004 年 2 月至 2007 年 3 月期间，在美国各地的 150 个地点共招募了 1120 名男性。这些男性的中位年龄为 73 岁（范围为 46-95 岁），主要为白人（77%），诊断时的中位 PSA 水平为 7.9ng/mL（范围为 0-710.8ng/mL）。登记入组时，观察（74%）是最常见的初始管理选择，而雄激素剥夺治疗（22%）是最常见的初始治疗选择。
来自 COMPARE 登记处的数据应该为 PSA 失败后前列腺癌的当代管理和患者结局提供有价值的前瞻性收集信息来源。
